I am Dr. Osama Ashry Ahmed Gheith, who graduated in 1987 from Mansoura faculty of medicine, Egypt. I have held an MD degree in Internal Medicine and Nephrology since 2003. I have been trained at Mansoura urology and nephrology center, Mansoura University, Egypt from 1991 till 2008 when I join the work at Hamed Al-Essa organ transplant center.
I am a member of the following societies: International Society of Nephrology (ISN), European Dialysis Transplantation Association (EDTA), African Association of Nephrology (AFRAN), Arab Society of Nephrology, and Egyptian Society of Nephrology (ESN).
I have long experience with all nephrology activities including all dialysis modalities, medical care of more than 3500 renal transplant recipients, and surgical Skills of importance in the field of nephrology as vascular access creation, PD catheter insertion, and renal biopsies. Moreover, I am interested in training and supervising Junior Staff in nephrology and renal transplant (in Egypt, Yemen, and Kuwait).
I have completed the NIH Web-based training course “Protecting Human Research Participants”. I am interested in research work and have over 12 research projects ongoing in the department. I am an author and/or co-author of over 85 publications in peer-reviewed international journals. In addition to several abstracts in many Middle East and international conferences. I am interested in the field of immunosuppression in renal transplantation, post-transplant diabetes, infection, and anemia.
I won some of the research prizes with the special concern of Emirates medical association –Nephrology Society EMAN YOUNG INVESTIGATOR AWARD –during the 12th congress of the Arab society of nephrology and renal transplantation 2014, 6th ISN EMAN Update Course in Nephrology 2014, 10-13December 2014 Dubai, UAE; one of the top 5 posters presented in ESNT 2018 (impact of HLA DR mismatch in elderly renal transplant recipients regardless donor sources: single-center experience from the middle east) and one of the top 5 posters presented in ESNT 2019 (Screening for BK viremia/viruria and the Impact of Management of BK Virus Nephropathy in Renal Transplant Recipients).
Acute kidney injury among COVID-19 positive patients is associated with higher mortality: single center experience
Torki M. AlOtaibi1, Osama Gheith1,2, Ayman M. Nagib1,2, Nabil Alserwy1, Ahmad M. Abbas1, Islam S. Elsawi1, Prasad Nair1, Mahmoud M. khaled1, Mohamed A. Hammad1, Zohair A. Fayyad1, Ahmed F. Atta1, Ahmed Y. Mostafa1, Ahmed S. Deraz1, Mohamed A. Moneim1.
1Nephrology , OTC kuwait, Kuwait, Kuwait; 2Nephrology , MUNC, mansoura, Egypt
Introduction: Despite the lungs being the major targets of COVID-19, other organs such as the kidneys are also affected. Renal complications of COVID-19 are not yet well studied.
Aim: We aimed to study the prevalence of acute kidney injury (AKI) among positive COVID-19 cases that were managed in the intensive care unit (ICU) in a single isolation hospital during the pandemic, and to explore its impact on patient outcome.
Methods: This retrospective study included 616 patients with COVID-19 who were managed in the ICU in a single isolation hospital in Kuwait during the pandemic, from February to December 2020. AKI was defined according to the serum creatinine criteria in the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Of the 616 patients, 40.2% developed AKI (group 1, n=248) and were compared with the patients without AKI (group 2, n=368).
Results: Most of the cases in the 2 groups were males (73% vs. 70.7%), aged (60.8± 14 vs. 51.7± 16 years) respectively. The 2 groups were comparable regarding chronic kidney disease (2% vs. 0.8%), and chronic pulmonary disease. Other factors were significantly predominating among group 1 as diabetes mellitus (63.7 vs. 40.5%), hypertension (74.2% vs. 40.5%), ischemic heart disease (26.2% vs. 12.5%) (p<0.05).
Fever, cough shortness of breath, and dehydration were significantly more frequent presentations among patients of group 1 and had radiological findings that were synchronized with COVID-19 (89.5% vs. 50.8%) (p<0.05). Moreover, sepsis, volume depletion, shock, arrhythmias, and ARDS predominated among the AKI group (P<0.05). The number of cases that were managed by therapeutic anticoagulation was significantly higher in AKI patients (89.9 % vs. 51.9%); also cases who received supportive vasopressors and convalescent plasma transfusion, as well as steroids, were significantly higher in the same group(p<0.05). Other therapeutic modalities such as antivirals, tocilizumab, and hydroxychloroquine were comparable in both groups.
We found that acute respiratory failure requiring mechanical ventilation was significant among the AKI group (66.8% vs. 29.4%), and the overall mortality rate was significantly higher in the same group (62.5%. vs. 32.8%).
Conclusion: The prevalence of AKI in patients with COVID-19 was 40.2%, and it was associated with poor prognosis among ICU covid-19 positive cases.
right-click to download